Overview

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul

Status:
Completed

Trial end date:
2018-05-14

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.

Phase:

Phase 4

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization